Vivint Pharma Injects ₹400 Crore into Hyderabad's Pharma Hub

In a groundbreaking move, Vivint Pharma, a leading name in injectables, has unveiled plans to invest ₹400 crore in a state-of-the-art injectables manufacturing facility in Genome Valley, Hyderabad. This strategic investment is poised to revolutionize the pharmaceutical landscape in the region and generate up to 1,000 new job opportunities.

The announcement came during a high-profile meeting with Telangana Chief Minister A. Revanth Reddy and his delegation, held in the United States. Vivint Pharma, renowned for its expertise in injectables, is set to expand its footprint in India with this new venture. The company, which has already established a research and development center in Genome Valley with an investment of approximately ₹70 crore, is now poised to take its commitment to the next level by setting up its first manufacturing plant.

The newly acquired 5.5-acre site in Genome Valley will be home to this cutting-edge facility, which will focus on the development and production of high-quality injectable drugs. With a specialized emphasis on oncology and critical care, the plant aims to address both domestic and international market demands.

Vivint Pharma’s expansion aligns with Telangana’s vision to bolster its pharmaceutical sector and enhance its global competitiveness. The new facility will not only contribute to the local economy through job creation but also strengthen India’s position in the global pharmaceutical industry.

The investment marks a significant milestone for Vivint Pharma, reflecting the company's confidence in the growth prospects of Hyderabad as a key hub for pharmaceutical manufacturing. As the facility takes shape, it promises to bring advanced drug solutions to patients worldwide and contribute to the ongoing evolution of the pharmaceutical sector in India.

News by Rahul Yelligetti